Innate Pharma S.A. (EPA:IPH)
1.538
+0.008 (0.52%)
Aug 3, 2026, 1:35 PM CET
Innate Pharma Employees
Innate Pharma had 164 employees as of December 31, 2025. The number of employees decreased by 17 or -9.39% compared to the previous year.
Employees
164
Change (1Y)
-17
Growth (1Y)
-9.39%
Revenue / Employee
€54,909
Profits / Employee
€299,860
Market Cap
143.70M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 164 | -17 | -9.39% |
| Dec 31, 2024 | 181 | 2 | 1.12% |
| Dec 31, 2023 | 179 | -32 | -15.17% |
| Dec 31, 2022 | 211 | -4 | -1.86% |
| Dec 31, 2021 | 215 | -29 | -11.89% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Valneva SE | 674 |
| Cellectis | 229 |
| Transgene | 145 |
| Adocia | 73 |
| OSE Immunotherapeutics | 64 |
| Fermentalg | 64 |
| Sensorion | 63 |
| MaaT Pharma | 59 |
Innate Pharma News
- 11 days ago - Innate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology Conference - Business Wire
- 13 days ago - Innate Pharma (IPHA) Completes Enrollment for Phase 1 Study of IPH4502 - GuruFocus
- 13 days ago - Innate Pharma completes enrollment in dose escalation of IPH4502 study - TheFly
- 13 days ago - Innate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC) - Business Wire
- 4 weeks ago - Innate Pharma Slides: Corporate presentation - Filings
- 2 months ago - Outcome of Innate Pharma's 2026 Annual General Meeting - Business Wire
- 2 months ago - Innate Pharma to participate in the Jefferies Global Healthcare Conference - Business Wire
- 2 months ago - Innate Pharma Q1 Earnings Call Highlights - MarketBeat